Cost-utility analysis of the insufflation of warmed humidified carbon dioxide during open and laparoscopic colorectal surgery [0.03%]
术中使用温湿化二氧化碳气体的费用效益分析——开腹与结直肠手术患者的成本效果分析
Michelle Jenks,Matthew Taylor,Judith Shore
Michelle Jenks
Background: An evaluation was conducted to estimate the cost-effectiveness of insufflation of warmed humidified CO2 during open and laparoscopic colorectal surgery compared with usual care from a UK NHS perspective. ...
Tracy L Skaer,Winghan Jacqueline Kwong
Tracy L Skaer
Fibromyalgia (FM) is a chronic syndrome that usually develops midlife. It is associated with a high burden of illness that causes significant disability. Areas covered: Diagnosis can be challenging, given the diverse clinical presentation a...
About the advantages and disadvantages of discrete-event simulation for health economic analyses [0.03%]
论离散事件模拟在卫生经济分析中的利弊
Mondher Toumi,Ekkehard Beck,Steve Sherman et al.
Mondher Toumi et al.
The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland [0.03%]
基于波兰药品报销的卫生技术评估建议的透明度
Tomasz Bochenek,Ewa Kocot,Marcin Rodzinka et al.
Tomasz Bochenek et al.
Background: The appropriate access to public information is very important for healthcare system stakeholders. The goal of this study was to examine how the execution of the formally existing right to public information o...
Productivity losses associated with cardiovascular disease: a systematic review [0.03%]
心血管疾病相关的生产力损失：一项系统综述
Adam L Gordois,Peter P Toth,Ruben Gw Quek et al.
Adam L Gordois et al.
People with cardiovascular disease (CVD) often require time off work to recover from illness or surgery; for example, following a myocardial infarction (MI) or stroke. These individuals incur income losses, work-related productivity is redu...
Reply: Letter to the Editor: About the advantages and disadvantages of discrete-event simulation for health economic analyses [0.03%]
致编辑的回信：关于离散事件模拟在卫生经济学分析中的利弊
J Jaime Caro,Jörgen Möller
J Jaime Caro
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations [0.03%]
欧洲医学肿瘤学会临床效益规模（ESMO-MCBS）在表皮生长因子受体活化突变的晚期非小细胞肺癌一线治疗酪氨酸激酶抑制剂关键III期随机对照试验中的应用
Jacopo Giuliani,Andrea Remo,Andrea Bonetti
Jacopo Giuliani
To examine the magnitude of the clinical benefit from first-line tyrosine kinase inhibitors (TKIs) advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR)-mutations. Areas covered: The present eva...
Simon B Zeichner,Christine G Kohn,Daniel A Goldstein
Simon B Zeichner
Despite its FDA approval and incorporation into the National Comprehensive Cancer Network (NCCN) treatment guidelines, ramucirumab (RAM) is associated with a drug acquisition cost that is substantially higher than other approved options. Gi...
Cost-effectiveness of professional pharmacy services in community pharmacy: a systematic review [0.03%]
社区药房专业药学服务的成本效益系统评价
A Malet-Larrea,V García-Cárdenas,L Sáez-Benito et al.
A Malet-Larrea et al.
The aim was to determine whether professional pharmacy services (PPS) provided to ambulatory patients attending community pharmacy are cost-effective compared with usual care (UC). Areas covered: MEDLINE, Web of Knowledge, Scopus, Cochrane ...
Outcome of the second Medicines Utilisation Research in Africa Group meeting to promote sustainable and appropriate medicine use in Africa [0.03%]
推动非洲合理用药的第二届医药利用研究非洲小组会议成果
Amos Massele,Johanita Burger,Francis Kalemeera et al.
Amos Massele et al.
The second Medicines Utilization Research in Africa (MURIA) group workshop and symposium again brought researchers together from across Africa to improve their knowledge of drug utilization (DU) methodologies and exchange ideas to further p...